Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.33 |
| ▸ | PREP | P48147 | 4/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.33 |
| ▸ | FAP | Q12884 | 6/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.32 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15107202 | 0.73 | DPP4 (0.39) | DPP4DPP7PREPDPP8DPP9 | |
| SCHEMBL17414386 | 0.71 | — | — | |
| SCHEMBL7838230 | 0.71 | — | — | |
| SCHEMBL65034 | 0.71 | — | — | |
| SCHEMBL7838226 | 0.71 | — | — | |
| SCHEMBL23925978 | 0.71 | — | — | |
| SCHEMBL12423934 | 0.71 | — | — | |
| SCHEMBL17301107 | 0.71 | POLB (0.44) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL17414350 | 0.71 | KMT2A (0.34) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL26723987 | 0.70 | CHRNB4 (0.30) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | DPP4 3391/4885DPP7 3853/4885PREP 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.